UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 60 filers reported holding UROGEN PHARMA LTD in Q2 2018. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,246 | +193.2% | 160,300 | +116.6% | 0.00% | +300.0% |
| Q2 2023 | $766 | +72.5% | 74,000 | +54.2% | 0.00% | 0.0% |
| Q1 2023 | $444 | +15.6% | 48,000 | +10.9% | 0.00% | 0.0% |
| Q4 2022 | $384 | -99.9% | 43,300 | +0.5% | 0.00% | 0.0% |
| Q3 2022 | $359,000 | +0.6% | 43,100 | -1.1% | 0.00% | – |
| Q2 2022 | $357,000 | +66.0% | 43,600 | +76.5% | 0.00% | – |
| Q1 2022 | $215,000 | -63.6% | 24,700 | -24.7% | 0.00% | -100.0% |
| Q4 2020 | $591,000 | +99.7% | 32,800 | +310.0% | 0.00% | – |
| Q1 2019 | $296,000 | -62.7% | 8,000 | -52.4% | 0.00% | -100.0% |
| Q3 2018 | $793,000 | -94.1% | 16,800 | -93.8% | 0.00% | -85.7% |
| Q2 2018 | $13,531,000 | +73.8% | 272,151 | +73.7% | 0.01% | -22.2% |
| Q1 2018 | $7,786,000 | +59.6% | 156,700 | +19.5% | 0.01% | +80.0% |
| Q4 2017 | $4,878,000 | +504.5% | 131,100 | +412.1% | 0.01% | +400.0% |
| Q3 2017 | $807,000 | – | 25,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |